title: [Pharmacovigilance update].
abstract: The main pharmacovigilance updates in 2015are reviewed. Sofosbuvir amiodarone interaction: risk of severe bradycardia. Dasabuvir clopidogrel interaction: increased dasabuvir concentrations and potential risk of QTprolongation. SGLT2 inhibitors: risks of diabetic acidocetosis and bone fracture. Dabigatran: therapeutic drug monitoring may improve benefit-risk ratio. Ibuprofen: at higher dosage, vascular risks are comparable to coxibs. Pregabaline, gabapentine: potential for abuse and addiction. Varenicline: potentiates alcohol's effects. Codeine: contra-indicated as cough medicine under the age of twelve. Valproate: strengthened warnings on the risks of valproate use in pregnancy. Dimethylfumarate: rare observations of progressive multifocal leucoencephalopathy. Ustekinumab: rare observations of erythrodermia.
authors.forename: Kim
authors.initials: K
authors.lastname: Dao
authors.forename: Haithem
authors.initials: H
authors.lastname: Chtioui
authors.forename: Laura E
authors.initials: LE
authors.lastname: Rothuizen
authors.forename: Léonore
authors.initials: L
authors.lastname: Diezi
authors.forename: Sylvain
authors.initials: S
authors.lastname: Prod'hom
authors.forename: Ursula
authors.initials: U
authors.lastname: Winterfeld
authors.forename: Thierry
authors.initials: T
authors.lastname: Buclin
authors.forename: Françoise
authors.initials: F
authors.lastname: Livio
mesh_terms: D016903:Drug Monitoring / Q000379:methods; D064420:Drug-Related Side Effects and Adverse Reactions / Q000209:etiology*; D006801:Humans; D060735:Pharmacovigilance